Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.85
Bid: 8.70
Ask: 9.00
Change: -0.15 (-1.67%)
Spread: 0.30 (3.448%)
Open: 9.00
High: 9.00
Low: 8.75
Prev. Close: 9.00
TEK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

29 Apr 2016 07:00

RNS Number : 7488W
Tekcapital plc
29 April 2016
 

 

 

Tekcapital plc

("Tekcapital", "the Company" or "the Group")

 

Preliminary Results for the year-ended 30 November 2015

 

Tekcapital plc (AIM:TEK), an international provider of technology and intellectual property services, announces its preliminary results for the year-ended 30 November 2015.

 

Operational Highlights

· Acquired the exclusive license rights to 50 patents to date.

· Continued to expand the InventionEvaluator® service with the addition of a direct sales team in the US and the recent upgrade to enhance both the content and marketability of the reports.

 

Post-period end highlights

· Acquisition of the business of the Vortechs Group, a leading technology transfer placement firm in North America.

· Acquisition of the exclusive licenses to manufacture and sell three proprietary medical devices from Stryker Corporation into Belluscura Ltd, a newly formed company set up by Tekcapital to commercialise these products.

 

Commenting on the results, Dr. Clifford Gross, Executive Chairman of Tekcapital plc said:

 

"We are pleased to announce we have continued to develop the business during 2015, which now holds license rights to a total of 50 patents. We remain confident that meaningful near-term revenues will arise from commercialising our IP portfolio."

 

"As the market opportunity for the Company continues to expand and large enterprises increasingly take advantage of exogenous innovations, the Company will continue to invest in its IP portfolio while evaluating further commercial opportunities for its existing licenses."

 

Copies of the Company's Annual Report and Accounts will be posted to shareholders next week, together with a notice of the Annual General Meeting to be held at 2.00 p.m. on 27 May 2016 at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD.

 

For further information, please contact:

 

Tekcapital plc

+1 305 200 3450 Ext 305

 

Clifford M. Gross

info@tekcapital.com

 

 

Allenby Capital Limited (Nominated Adviser & Joint Broker)

+44 (0)20 3328 5656

Jeremy Porter / Alex Brearley

 

 

 

Optiva Securities Limited (Joint Broker)

+44 (0) 20 3137 1904

Jeremy King / Vishal Balasingham

jeremy.king@optivasecurities.com

 

 

Walbrook PR Ltd

+44 (0) 20 7933 8780

Paul Cornelius / Helen Cresswell / Sam Allen

tekcapital@walbrookpr.com

   
 

 

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital helps clients profit from new, university-developed intellectual properties. With our proprietary discovery search engine, linked to 4,000+ universities in 160 countries, coupled with expert scientific review, we provide a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is listed on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com 

 

 

Chairman's statement

 

Review of the Business

 

The Tekcapital group is engaged in helping its clients to profit from university intellectual property (IP). Since last year we have made considerable progress.

 

We continue to provide technology sourcing services for our corporate clients but also provide three important additional services:

 

· Acquiring the exclusive license to potentially disruptive technologies for our own portfolio for subsequent development and commercialisation. Since we began this service in January 2015, to-date we have acquired the exclusive rights to 50 patents.

 

· In 2014 we announced the acquisition of InventionEvaluator, the turn-key service that assesses the commercial potential of new technologies. We continue to expand the client base for the service and have added a direct sales team in our US office. Additionally, we have recently up-graded the format of the reports to enhance both their information content and marketability.

 

· Post end of period we were very pleased to have announced the acquisition of the business and certain assets of the Vortechs Group, a leading technology transfer placement firm in North America. For operating the Vortechs Group's business on behalf of Tekcapital and for covering all related business expenditures going forward, Tekcapital will pay Vortechs Group a management and service fee, based on revenue achieved, for a minimum period of five years. This expands our business offerings and enables us to provide technology transfer professionals as well as new technologies to both our clients and university suppliers.

 

Additionally, post end of period we are pleased to have also announced the acquisition of the exclusive licences to manufacture and sell three proprietary medical devices from Stryker Corporation into Belluscura Ltd, a newly formed company set up by Tekcapital to commercialise these products. Belluscura Ltd's mission is to address the marketplace need for premium medical devices at affordable prices. The devices have been developed by and exclusively licensed from Stryker Corporation, a leading medical technology company. The devices have achieved regulatory clearances where necessary and have already achieved commercial sales under Stryker.

 

The medical devices are:

· "SlydeTM", a non-ambulatory patient evacuation sled.

· "Passport", a trocar for use with the Da Vinci® Surgical System (keyhole surgery).

· "SNAP II", a level of consciousness monitor for use during surgical procedures requiring general anaesthesia.

 

The products are protected by a portfolio of 19 issued and pending patents and industrial designs. Belluscura has been established in order to commercialise these products, for which a new management team is being put in place. It is intended that Belluscura will market and expand the sales of the devices, initially in the US and Western Europe, using third party manufacturing and will look to acquire additional medical devices to sell in the future. Tekcapital is exploring the possibility of Belluscura raising funds via an IPO on AIM to accelerate its growth strategy. Tekcapital owns 95% of the share capital of Belluscura and Stryker Corporation owns the remaining 5%. 

 

 

Divisional Review

 

Demand for the Group's Invention Evaluator service remains strong with customers consisting of universities, research centres and corporations world-wide. The service has been successfully integrated with our existing offering and has attracted significant interest.

 

The Group's technology out-licensing service leverages its competencies to identify and acquire particularly promising new IP which management believes can be readily out-licensed to corporations. This service extends the Group's impact by directly commercialising innovative university and corporate developed technologies and also has the potential to capture for the Group's own benefit more of the value realised when innovative ideas are successfully commercialised. Since inception a year ago, this new effort has grown rapidly. As of the date of this report we have secured exclusive licenses to 50 patents, applications and industrial designs. We have a number of on-going commercialisation opportunities that we hope to progress in the near future. We are making solid progress on our commercialisation programmes for a number of our licensed properties and believe that we will be in a position to update the market in due course. The Directors believe that the post period announcements of the acquisition of the Vortechs Group business and the establishment of Belluscura Ltd should make a significant contribution to our Group's financial performance in future reporting periods.

 

Current Trading and Outlook

 

Having continued to develop its existing business, the Board is confident that continued investment in growth is the right policy. We believe this strategy is likely to lead to increased revenue in 2016 as we continue to seize additional opportunities with the potential for adding considerable shareholder value.

 

The Directors remain confident that meaningful revenues will arise from our service offerings combined with the near-term sub-licensing or external funding of licenses held in its IP portfolio. With an increasing number of companies making ever faster and more disruptive use of innovative ideas sourced exogenously, and with patented university and corporate technologies an increasingly valued currency, the market opportunity for the Group is both large and continuing to grow.

 

Financial review

 

The Group is still in its early stages of development. Funds raised from investors are being applied, along with revenues generated, to pursuing our strategic objectives. These are principally to grow the customer base for our technology transfer services and to acquire and sell on licences for certain university and corporate intellectual properties.

 

Group sales for the period to 30 November 2015 were US $407,420 (as compared with sales of US $210,337 in 2014) with losses of US $1,460,815 as compared with losses of US $994,869 in 2014.

 

The Group's assets grew from US $1,818,352 to US $3,961,698 during the period mainly thanks to shareholder investment during the year, augmented by technology acquisitions. The Group's liabilities are very low at the end of the period because its costs have been settled without delay, using funds from the cash reserves invested since our IPO and subsequent capital raise in May of 2015.

 

Clifford M Gross

Chairman and CEO

28 April 2016 

Consolidated Statement of comprehensive income

For the year ended 30 November 2015

 

 

Group

 

 

Note

 

 

Year ended 30 November 2015

 

Year end

30 November 2014

 

 

 

US $

US $

 

 

 

 

 

Continuing Operations

 

 

 

 

Revenue

3

 

407,420

210,337

 

 

 

 

 

Gross Profit

 

 

407,420

210,337

 

 

 

 

 

Administrative expenses

 

 

(1,868,124)

(1,123,936)

Foreign exchange movements

 

 

-

(80,112)

 

 

 

 

 

Operating Loss

 

 

(1,460,704)

(993,711)

 

 

 

 

 

Finance income

 

 

709

142

 

 

 

 

 

 

 

 

 

 

Loss on ordinary activities before income tax

 

 

(1,459,995)

(993,569)

Income tax expense

4

 

(820)

(1,300)

 

 

 

 

 

Loss after tax

 

 

(1,460,815)

(994,869)

 

 

 

 

 

Loss for the year attributable to owners of the parent company

 

 

(1,460,815)

(994,869)

 

 

 

 

 

Other comprehensive income

 

 

 

 

Foreign exchange gain

 

 

47,851

-

Total other comprehensive income

 

 

47,851

-

 

 

 

 

 

Total comprehensive income for the year attributable to owners of the parent company

 

 

(1,412,964)

(994,869)

 

 

 

 

 

Loss per share

Basic and diluted earnings per share

 

 

 

 

Loss per share

5

 

(0.049)

(0.050)

 

 

 

 

 

 

The Group has used the exemption under S408 CA 2006 not to disclose the company income statement. Items in the statement above are disclosed net of tax.

 

 

Consolidated Statement of financial position

At 30 November 2015

 

 

 

Group

 

 

Note

 

 

As at

 30 November 2015

 

As at

30 November 2014

 

 

 

US $

US $

Assets

 

 

 

 

Non-current assets

 

 

 

 

Intangible assets

7

 

708,577

350,251

Property, plant and equipment

 

 

7,920

6,628

 

 

 

716,497

356,879

 

 

 

 

 

Current assets

 

 

 

 

Trade and other receivables

 

 

105,955

90,568

Cash and cash equivalents

 

 

3,139,246

1,370,905

 

 

 

3,245,201

1,461,473

 

 

 

 

 

Total assets

 

 

3,961,698

1,818,352

 

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

 

 

241,181

100,052

Current income tax liabilities

 

 

1,300

1,300

 

 

 

242,481

101,352

 

 

 

 

 

Total liabilities

 

 

242,481

101,352

 

 

 

 

 

Net assets

 

 

3,719,217

1,717,000

 

 

 

 

 

Equity attributable to the owners of the parent

 

 

 

 

Ordinary shares

 

 

224,684

154,842

Share premium

 

 

5,980,751

2,673,905

Retained earnings

 

 

(2,461,900)

(1,039,578)

Translation reserve

 

 

47,851

-

Merger reserves

 

 

(72,169)

(72,169)

 

 

 

 

 

Total equity

 

 

3,719,217

1,717,000

 

 

 

 

 

 

 

 

 

 

 

 

 

Statement of financial position

At 30 November 2015

 

 

 

Company

 

 

Note

 

 

As at

 30 November 2015

 

As at

30 November 2014

 

 

 

US $

US $

Assets

 

 

 

 

Non-current assets

 

 

 

 

Intangible assets

7

 

19,081

29,701

Investment in subsidiaries

6

 

2,371,820

2,371,820

 

 

 

2,390,901

2,401,521

 

 

 

 

 

Current assets

 

 

 

 

Trade and other receivables

 

 

3,128,780

-

Cash and cash equivalents

 

 

37,256

-

 

 

 

3,166,036

-

 

 

 

 

 

Total assets

 

 

5,556,937

2,401,521

 

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

 

 

412,568

8,009

 

 

 

 

 

 

 

 

412,568

8,009

 

 

 

 

 

Total liabilities

 

 

412,568

8,009

 

 

 

 

 

Net assets

 

 

5,144,369

2,393,512

 

 

 

 

 

Equity attributable to the owners of the parent

 

 

 

 

Ordinary shares

 

 

224,684

154,842

Share premium

 

 

5,980,751

2,673,905

Retained earnings

 

 

(1,028,925)

(435,235)

Translation reserve

 

 

(32,141)

-

 

 

 

 

 

Total equity

 

 

5,144,369

2,393,512

 

 

 

 

 

 

 

 

Statements of changes in equity

For the year ended 30 November 2015

 

Group

 

Note

Ordinary Shares

US $

Share Premium

US $

Translation Reserve

US $

Merger reserve

US $

Retained earnings

US $

Total Equity

US $

Balance at 30 November 2013

 

94,953

-

-

(72,159)

(44,709)

(21,915)

Loss for the year

 

-

-

-

-

(994,869)

(994,869)

Acquired with new subsidiary

 

-

-

-

(10)

-

(10)

Share capital issued on initial public offering

 

59,889

3,598,553

-

-

-

3,658,442

Costs of share issue

 

-

(924,648)

-

-

-

(924,648)

Balance at 30 November 2014

 

154,842

2,673,905

-

(72,169)

(1,039,578)

1,717,000

 

 

 

 

 

 

 

 

Loss for the year

 

-

-

-

-

(1,460,815)

(1,460,815)

Other comprehensive income

 

 

 

47,851

 

-

47,851

Share based payments

 

-

-

-

-

38,493

38,493

Issue of Ordinary shares net of costs

 

69,270

3,436,126

-

-

-

3,505,396

Costs of share issue

 

-

(164,456)

-

-

-

(164,456)

Warrants exercised

 

572

35,176

-

-

-

35,748

Balance at 30 November 2015

 

224,684

5,980,751

47,851

(72,169)

(2,461,900)

3,719,217

 

 

 

 

 

 

 

 

 

 

 

Company

 

 

Note

 

Ordinary Shares

US $

 

Share Premium

US $

 

Translation Reserve

US $

 

Retained earnings

US $

 

Total Equity

US $

Balance at 30 November 2013

 

-

-

-

-

-

Loss for the year

 

-

-

-

(435,235)

(435,235)

Proceeds from shares issued

 

154,842

3,598,553

-

-

3,753,395

Costs of share issue

 

-

(924,648)

-

-

(924,648)

Balance at 30 November 2014

 

154,842

2,673,905

-

(435,235)

2,393,512

 

 

 

 

 

 

 

Loss for the year

 

-

-

-

(632,183)

(632,183)

Other comprehensive income

 

-

-

(32,141)

-

(32,141)

Share based payments

 

-

-

-

38,493

38,493

Issue of Ordinary shares net of costs

 

69,270

3,436,126

-

-

3,505,396

Costs of share issue

 

-

(164,456)

-

-

(164,456)

Warrants exercised

 

572

35,176

-

-

35,748

Balance at 30 November 2015

 

224,684

5,980,751

(32,141)

(1,028,925)

5,144,369

 

 

Consolidated Statement of cash flows

For the year ended 30 November 2015

 

 

 

Group

 

 

Note

 

For the year ended

 30 November 2015

For the year ended 

30 November 2014

 

 

 

US $

US $

Cash flows from operating activities

 

 

 

 

Cash generated from operations

9

 

(1,222,474)

(1,014,434)

Taxation paid

 

 

(820)

-

 

 

 

 

 

Net cash generated from operating activities

 

 

(1,223,294)

(1,014,434)

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

Purchases of property, plant and equipment

 

 

(4,349)

(8,631)

Purchases of intangible assets

 

 

(162,080)

(33,306)

Interest received

 

 

709

142

 

 

 

 

 

Net cash used in investing activities

 

 

(165,720)

(41,795)

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

Proceeds from issuance of ordinary shares

 

 

3,286,060

3,337,882

Costs of raising finance

 

 

(164,456)

(924,648)

Proceeds from the exercise of warrants

 

 

35,751

-

 

 

 

 

 

Net cash used in financing activities

 

 

3,157,355

2,413,234

 

 

 

 

 

Net increase in cash and cash equivalents

 

 

1,768,341

1,357,005

Cash and cash equivalents at beginning of year

 

 

1,370,905

13,900

 

 

 

 

 

Cash and cash equivalents at end of year

 

 

3,139,246

1,370,905

 

 

 

 

 

 

 

 

 

Selected Notes to the accounts

For the year ended 30 November 2015

1. General Information

Tekcapital PLC is a company incorporated in England and Wales and domiciled in the UK. The address of the registered office is detailed on page 1 of these financial statements. The Company is a public limited company, which is listed on the AIM market of the London Stock Exchange.

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Statement of compliance

The financial statements of Tekcapital PLC have been prepared in accordance with International Financial Reporting Standards (IFRS) and IFRS Interpretations Committee (IFRS IC) as adopted by the European Union and the Companies Act 2006 applicable to companies reporting under IFRS. The financial statements have been prepared under the historical cost convention.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It requires management to exercise its judgement in the process of applying the group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in note 4.

2.1.1 Going concern

The Group meets its day to day working capital requirements through its bank facilities and monies raised by an initial public offering made April 2014 and an equity fundraise in May 2015. The Group's forecasts and projections indicate that the Group has sufficient cash reserves to operate within the level of its current facilities. After making enquiries, the Directors have a reasonable expectation that the Group had adequate resources to continue in operational existence for the foreseeable future.

The Group delivered an operating loss of US$1,460,704 before tax. Cash inflow from financing activities was strong due to the equity fund raise in May 2015.

The Company therefore continues to adopt the going concern basis in preparing both its consolidated financial statements and for its own financial statements. 

3. Segmental reporting

The Directors consider the business to have two segments for reporting purposes under IFRS 8 which are:

· professional services, including the provision of reports and any services provided to locate and transfer technologies to customers

· licensing activities, including acquiring licenses for technologies and their subsequent out licensing

 

 

Segmental revenues and results

2015

Consolidated income statement

Professional Services

US $

Licensing Activities

US $

 

Other

US $

 

Total

US $

Revenue

407,420

-

-

407,420

Administrative expenses

(328,862)

(35,000)

(1,478,118)

(1,841,980)

Depreciation and amortisation

-

(12,467)

(13,677)

(26,144)

 

 

 

 

 

Group operating income/(loss)

78,558

(47,467)

(1,491,795)

(1,460,704)

Finance income

-

-

709

709

 

 

 

 

 

Income/(Loss) on ordinary activities before income tax

78,558

(47,467)

(1,491,086)

(1,459,995)

Income tax expense

-

-

(820)

(820)

 

 

 

 

 

Income/(Loss) after tax

78,558

(47,467)

(1,491,906)

(1,460,815)

 

2014

Consolidated income statement

Professional Services

US $

Licensing Activities

US $

 

Other

US $

 

Total

US $

Revenue

210,337

-

-

210,337

Administrative expenses

(240,106)

-

(878,222)

(1,118,328)

Depreciation and amortisation

-

-

(5,608)

(5,608)

Foreign exchange movements

-

-

(80,112)

(80,112)

 

 

 

 

 

Group operating loss

(29,769)

-

(963,942)

(993,711)

Finance income

-

-

142

142

 

 

 

 

 

Loss on ordinary activities before income tax

(29,769)

-

(963,800)

(993,569)

Income tax expense

 

 

(1,300)

(1,300)

 

 

 

 

 

Loss after tax

(29,769)

-

(965,100)

(994,869)

 

 

 

 

 

 

 

 

Segment assets and liabilities

2015

Consolidated statement of financial position

Professional Services

US $

Licensing Activities

US $

 

Other

US $

 

Total

US $

Assets

378,917

365,761

3,217,020

3,961,698

Liabilities

-

-

(242,481)

(242,481)

 

 

 

 

 

Net assets

378,917

365,761

2,974,539

3,719,217

 

 

 

 

 

 

2014

Consolidated statement of financial position

Professional Services

US $

Licensing Activities

US $

 

Other

US $

 

Total

US $

Assets

369,335

-

1,449,017

1,818,352

Liabilities

-

-

(101,352)

(101,352)

 

 

 

 

 

Net assets

369,335

-

1,347,665

1,717,000

 

 

 

 

 

Geographical information

Disclosure of Group revenues by geographic location.

 

 

2015

US $

2014

US $

United Kingdom

 

4,598

32,576

United States

 

402,822

177,761

Total revenue

 

407,420

210,337

 

 

 

 

     

 

 

 

4. Income tax expense

Group

 

2015

US $

2014

US $

Current tax

 

 

 

Current tax on profits for the year

 

820

1,300

Adjustments in respect of prior year

 

-

-

Total current tax

 

820

1,300

 

 

 

 

Income tax expense

 

820

1,300

 

 

 

 

 

Group

 

2015

US $

2014

US $

(Loss) before tax

 

(1,459,995)

(993,569)

Tax calculated at domestic tax rates applicable to profits in the respective countries

 

(291,999)

(198,714)

Tax effects of:

 

 

 

- Unrecognised and unused tax losses carried

 

-

-

- Expenses not deductible for tax purposes

 

9,118

-

- Income not taxable for tax purposes

 

-

(11,204)

- Capital allowances in excess of depreciation

 

1,865

(9,612)

- Unrelieved tax losses and other deductions

 

281,836

220,830

Total income tax charge

 

820

1,300

 

 

 

 

The tax on the Group's loss before tax differs from the theoretical amount that would arise using the weighted average tax rate applicable to losses.

The weighted average applicable tax rate was 20%. The increase is caused by a standard amount of tax payable in those States in the USA which a subsidiary company operates from and is not attributable to the level of profits or losses incurred.

Unused tax losses for which no deferred tax assets have been recognised is attributable to the uncertainty over the recoverability of those losses through future profits.

 

5. Loss per share

 

 

2015

US $

2014

US $

Loss from continuing operations attributable to owners of the parent

 

(1,460,815)

(994,869)

Total

 

(1,460,815)

(994,869)

 

 

 

 

Basic and diluted earnings per share

 

 

 

Weighted average number of ordinary shares in issue (000's)

 

29,902

20,078

Loss per share

 

(0.049)

(0.050)

 

 

 

 

Any options and warrants do not have a dilutive effect on the EPS as the Group is loss-making.

 

 

6. Investments in subsidiaries

Company

Shares in subsidiaries

Loans to subsidiaries

Total

US $

Cost and net book value

 

 

 

At 1 December 2013

-

-

-

Additions during the year

94,954

2,276,866

2,371,820

Balance at 30 November 2014

94,954

2,276,866

2,371,820

Additions during the year

-

-

-

Balance at 30 November 2015

94,954

2,276,866

2,371,820

 

 

 

 

Principal subsidiaries name

Country of Incorporation and place of business

Proportion of ordinary shares directly held

Nature of business

 

Tekcapital Europe Limited

England and Wales

100%

Provision of Intellectual property research services

 

Tekcapital LLC

USA

100%

Provision of Intellectual property research services

 

Non Invasive Glucose Tek Limited (*)

England and Wales

100%

Commercialising Intellectual property

 

Ocutek Limited (*)

England and Wales

100%

Commercialising Intellectual property

 

Smart Food Tek Limited (*)

England and Wales

100%

Commercialising Intellectual property

 

eGravitas Limited (*)

England and Wales

100%

Commercialising Intellectual property

 

Frigidus Limited (*)

England and Wales

100%

Commercialising Intellectual property

 

eSoma Limited (*)

England and Wales

100%

Commercialising Intellectual property

 

        

* 100% subsidiary of Tekcapital Europe Limited

The Group owns 100% of the above subsidiaries and consequently has full control over them. As at the year end, the Group has no interest in the ownership of any other entities, or exerts any significant influence over or provides funding which constitutes an "unconsolidated structured entity".

All UK subsidiaries are exempt from the requirement to file audited accounts by virtue of section 479A of the Companies Act 2006. As part of this process, the Company has provided statutory guarantees to these subsidiaries.

The Company's loss before tax for the year ended 30 November 2015 was $632,183.

 

 

 

7. Intangible assets

 

Purchased intangible assets

Group

 

Licenses

US $

Website development

US $

Invention Evaluator

US $

 

Total

US $

At 1 December 2013

-

-

-

-

Additions during the year

-

33,306

320,550

353,856

At 30 November 2014

-

33,306

320,550

353,856

Additions during the year

378,228

-

3,185

381,413

 

 

 

 

 

At 30 November 2015

378,228

33,306

323,735

735,269

 

 

 

 

 

Accumulated amortisation and impairment

 

 

 

 

At 1 December 2013

-

-

-

-

Amortisation charge for the year

-

(3,605)

-

(3,605)

At 30 November 2014

-

(3,605)

-

(3,605)

Amortisation charge for the year

(12,467)

(10,620)

 

(23,087)

 

 

 

 

 

At 30 November 2015

(12,467)

(14,225)

-

(26,692)

 

 

 

 

 

Net book value

 

 

 

 

At 30 November 2014

-

29,701

320,550

350,251

 

 

 

 

 

At 30 November 2015

365,761

19,081

323,735

708,577

 

Under IAS38, the Group's Invention Evaluator is regarded by the Directors as being an intangible asset with an indefinite useful life. The Directors believe that the asset is unique in that no competitor offering currently exists, the service is already proven to have appeal globally to many types of clients including Fortune 100 companies, there is no expectation of obsolescence in the foreseeable future, and the service generates sufficient on-going revenue streams. The Directors have carried out an impairment review and believe that the value in use is significantly greater than book value.

 

 

 

 

Purchased intangible assets

Company

 

Website development

US $

 

Total

US $

At 1 December 2013

 

-

-

Additions during the year

 

33,306

33,306

At 30 November 2014

 

33,306

33,306

Additions during the year

 

-

-

 

 

 

 

At 30 November 2015

 

33,306

33,306

 

 

 

 

Accumulated amortisation and impairment

 

 

 

At 1 December 2013

 

-

-

Amortisation charge for the year

 

(3,605)

(3,605)

At 30 November 2014

 

(3,605)

(3,605)

Amortisation charge for the year

 

(10,620)

(10,620)

 

 

 

 

At 30 November 2015

 

(14,225)

(14,225)

 

 

 

 

Net book value

 

 

 

At 30 November 2014

 

29,701

29,701

 

 

 

 

At 30 November 2015

 

19,081

19,081

 

8. Dividends

No dividend has been declared for the year ended 30 November 2015 (2014: Nil) and no dividend was paid during the year.

 

9. Cash generated from operations

Group

 

2015

US $

2014

US $

Loss before income tax

 

(1,459,995)

(993,569)

Adjustments for

 

 

 

- Depreciation

 

3,057

2,003

- Amortisation

 

23,087

3,605

- Finance costs - net

 

(709)

(142)

- Share based payments expense

 

38,493

-

- Movement in foreign exchange

 

47,851

-

Movement in trade and other receivables

 

(15,387)

(78,658)

Movement in trade and other payables

 

141,129

52,354

Cash generated

 

(1,222,474)

(1,014,434)

 

 

 

 

10. Events after the reporting period

At the time of signing these accounts, the Directors had completed the acquisition of the business of the Vortechs Groups Inc. ("Vortechs Group"). Consideration for the acquisition was by way of $100,000 cash and the issue of 577,868 new ordinary share of 0.4 pence to Vortechs Group at an issue price of £0.475 per share.

The acquisition has been structured so that Tekcapital acquires the intellectual capital assets of Vortechs Group and certain other assets of the business. Tekcapital will not acquire the Vortechs Group corporate entity and certain of its fixed assets. Additionally, Tekcapital will not acquire or assume any of Vortechs Group's liabilities.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR ZMGZDMRFGVZZ
Date   Source Headline
28th Mar 202410:20 amRNSNotification of Major Holdings
7th Mar 202411:15 amRNSNotification of Major Holdings
6th Mar 20247:00 amRNSIntellectual Property Update
29th Feb 20247:51 amRNSFundraising of £2.0 million
19th Feb 20247:00 amRNSPortfolio Company Update : Guident Ltd
15th Feb 202410:31 amRNSNotification of Major Holdings
15th Feb 20247:00 amRNSGuident Expands its Strategic Partnership
13th Feb 20242:24 pmRNSNotification of Major Holdings
1st Feb 20247:15 amRNSMicroSalt Admission to AIM First Day of Dealings
1st Feb 20247:01 amRNSNotice of Presentation on Investor Meet Company
24th Jan 20247:00 amRNSBellescura Plc - Disposal of Shares
12th Jan 20244:31 pmRNSLoan Agreement with Innovative Eyewear Inc
11th Jan 20247:00 amRNSInnovative Eyewear Patent Applications
9th Jan 20247:00 amRNSMicroSalt expand Placement Low Sodium Salt Shakers
22nd Dec 20237:00 amRNSAnnual Corporate & Strategy Update
14th Dec 20237:00 amRNSInnovative Eyewear Appoints Brand Ambassador
13th Dec 20237:00 amRNSInnovative Eyewear Update for Android ChatGPT App
12th Dec 20237:00 amRNSInnovative Eyewear,Inc. Global Licensing Agreement
17th Nov 20237:00 amRNSInnovative Eyewear Launches Upgraded Charging Dock
16th Nov 202312:12 pmRNSForm 8.3 - Belluscura PLC
1st Nov 20237:00 amRNSMicroSalt placement SaltMe! Crisps in MR Williams
19th Oct 20237:00 amRNSMicroSalt placement of SaltMe Low Sodium Crisps
17th Oct 20237:00 amRNSInnovative Eyewear Launches New Collection
16th Oct 20237:00 amRNSTakeover Code Form 8.3 - Belluscura plc
5th Oct 20237:00 amRNSBelluscura Update
5th Oct 20237:00 amRNSNotification of Major Holdings
3rd Oct 20238:00 amRNSMicroSalt Primary Bid Offer Files Schedule One
29th Sep 20238:00 amRNSHalf Yearly Report for period ending 30 June 2023
19th Sep 20237:00 amRNSMicroSalt Partnership with Weijohn Farms Group
13th Sep 20234:15 pmRNSNotification of Major Holdings
11th Sep 20237:00 amRNSInnovative Eyewear Announces Patent Filing
7th Sep 20237:00 amRNSMicroSalt files New Patent to Improve Baked Goods
6th Sep 20237:00 amRNSGuident Update
24th Aug 20237:00 amRNSPortfolio Company Update - Guident
17th Aug 20237:00 amRNSPortfolio Companies Update
14th Aug 20237:00 amRNSLucyd ChatGPT App Update for Smart Eyewear
1st Aug 20237:00 amRNSInnovative Eyewear Launches Lucyd Blueshift Lens
31st Jul 20237:00 amRNSMicroSalt commercial orders for SaltMe Crisps
30th Jun 20237:00 amRNSInnovative Eyewear Miami Fashion Week
28th Jun 20237:00 amRNSInnovative Eyewear Partnership with PRIVATO
26th Jun 20237:00 amRNSMicroSalt Expands U.S. Retail Network
22nd Jun 20231:38 pmRNSResults of Annual General Meeting
22nd Jun 20231:27 pmRNSInnovative Eyewear US$ 4.7Million Public Offering
20th Jun 20237:00 amRNSInnovative Eyewear Licensing Agreement for Reebok
16th Jun 20237:00 amRNSSpace Florida Awards Grant to Guident and NOVELSAT
14th Jun 20237:00 amRNSGuident Secures New Patent
26th May 20237:00 amRNSFinal Results Year ended 31 December 2022
18th May 20237:00 amRNSMicroSalt Jack Stein appointed Brand Ambassador
17th May 20237:00 amRNSMicroSalt expands U.S. retail presence
4th May 20234:40 pmRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.